X-Therma logo

XT-VIVO® & TIMESEAL®

Multi-Day Preservation of Organs, Tissues and Cells

The global shortage of transplantable organs is considered one of the greatest modern medical crises. Only 10% of the worldwide transplantation needs are being met. Every hour in the US, at least one patient dies while waiting for a life-saving organ. Donor availability is one part of the equation… the other is time. 

XT-ViVo® & TimeSeal® will enable multi-day preservation and remove time from the equation. Check out our white paper on organ ischemia to learn more!

Organ Transplant

Not Enough Time

Do you know 80% of transplantable organs end up NOT being transplanted today, especially for hearts and lungs?

1/hour

Die on waitlist

80%

transplantable organs left unused

Just hours

to keep organs alive

In organ transplantation, we are racing against TIME on Ice every day, battling an extremely slim window where every minute matters. We currently perfuse and store an organ in preservation solution that is kept between 2-8°C in an igloo cooler on wet-ice. This only allows organ survival for less than a day. For the heart, that is an ephemeral 4 hrs. This extremely tight race severely hinders organ accessibility, breeds extreme risk, creates a logistics nightmare for the transplant team and significantly impacts patient survival. 

To win such a race, we MUST remove TIME from the equation. 

With X-Therma’s biopreservation breakthroughs, we make a difference.

cGMP CELL & GENE THERAPY

DMSO and Serum No Longer Meet Integrated Demands

Poor Performance
  • Poor post-thaw cell survival as low as 15-20%
  • Cell functionality impaired
Toxic
  • Profound in vivo toxicity
  • Severe injection site pain/neurotoxicity
  • Adverse Genotoxicity

Nature, Scientific Reports volume 9, Article number: 4641 (2019)

Hindered Scalability
  • Processing nightmare
  • Limited scale-up production
  • Batch variation

Biopreservation is the key for commercial cell manufacturing & processing, which happens 3-5 times throughout the process. However, preservation has seen little improvement. Existing standards use 5-10% dimethyl sulfoxide (DMSO) with serum. A new solution is needed to enable “off-the-shelf” living medicines.

In Vitro Fertilization

Can we say “No” to toxins for healthy babies?

DMSO

Adverse Toxicity & Genotoxicity

Poor Functional Recovery <10% (human eggs)

In Vitro Fertilization uses a high concentration of toxic vitrification media to freeze eggs or embryos that can kill a cat just in one teaspoon taken orally. This causes severe cell shrinkage and damage to the cell membrane, ultimately leading to a negative impact on the viability of the eggs, giving less than 10% with functional recovery.

The extreme changes in microRNAs and alterations in the epigenetic landscape indicate that DMSO is not inert. Its use should be reconsidered, especially for preservation of embryos and oocytes, since it may impact embryonic development.

Nature, Scientific Reports volume 9, Article number: 4641 (2019)

Organ Transplant

Not Enough Time

Do you know 80% of transplantable organs end up NOT being transplanted today, especially for hearts and lungs?

90%

UNMET NEED
1/hour

Die on waitlist

80%

transplantable organs left unused

Just hours

to keep organs alive

In organ transplantation, we are racing against TIME on Ice every day, battling an extremely slim window where every minute matters. We currently perfuse and store an organ in preservation solution that is kept between 2-8°C in an igloo cooler on wet-ice. This only allows organ survival for less than a day. For the heart, that is an ephemeral 4 hrs. This extremely tight race severely hinders organ accessibility, breeds extreme risk, creates a logistics nightmare for the transplant team and significantly impacts patient survival. 

To win such a race, we MUST remove TIME from the equation. 

cGMP CELL & GENE THERAPY

DMSO and Serum No Longer Meet Integrated Demands

Poor Performance
  • Poor post-thaw cell survival as low as 15-20%
  • Cell functionality impaired
TOXIC
  • Profound in vivo toxicity
  • Severe injection site pain/neurotoxicity
  • Adverse Genotoxicity

Nature, Scientific Reports volume 9, Article number: 4641 (2019)

HINDERED SCALABILITY
  • Processing nightmare
  • Limited scale-up production
  • Batch variation

Biopreservation is the key for commercial cell manufacturing & processing, which happens 3-5 times throughout the process. However, preservation has seen little improvement. Existing standards use 5-10% dimethyl sulfoxide (DMSO) with serum. A new solution is needed to enable “off-the-shelf” living medicines.

cGMP CELL & GENE THERAPY

DMSO and Serum No Longer Meet Integrated Demands

Poor Performance
  • Poor post-thaw cell survival as low as 15-20%
  • Cell functionality impaired
Toxic
  • Profound in vivo toxicity
  • Severe injection site pain/neurotoxicity
  • Adverse Genotoxicity

Nature, Scientific Reports volume 9, Article number: 4641 (2019)

Hindered Scalability
  • Processing nightmare
  • Limited scale-up production
  • Batch variation

Biopreservation is the key for commercial cell manufacturing & processing, which happens 3-5 times throughout the process. However, preservation has seen little improvement. Existing standards use 5-10% dimethyl sulfoxide (DMSO) with serum. A new solution is needed to enable “off-the-shelf” living medicines.

In Vitro Fertilization

Can we say “No” to toxins for healthy babies?

DMSO

Adverse Toxicity & Genotoxicity

Poor Functional Recovery <10% (human eggs)

In Vitro Fertilization uses a high concentration of toxic vitrification media to freeze eggs or embryos that can kill a cat just in one teaspoon taken orally. This causes severe cell shrinkage and damage to the cell membrane, ultimately leading to a negative impact on the viability of the eggs, giving less than 10% with functional recovery.

The extreme changes in microRNAs and alterations in the epigenetic landscape indicate that DMSO is not inert. Its use should be reconsidered, especially for preservation of embryos and oocytes, since it may impact embryonic development.

Nature, Scientific Reports volume 9, Article number: 4641 (2019)

With X-Therma’s biopreservation breakthroughs, we make a difference. 

You Have Time

Our solutions provide significantly longer preservation of organs, cells, and tissues.

FDA Breakthrough Designation

The FDA has granted XT-ViVo® & TimeSeal® Breakthrough Device Designatiofor an intended kidney preservation and storage time of up to 120 hours. The products also have the potential to be used in other organ and tissue applications.

Extended Kidney Storage Time Up to 120 Hours
surgeons working

YOU NOW HAVE THE TIME WITH

XT-ViVo® Preservation

XT-ViVo® is a non-toxic, serum- and protein-free, completely defined organ preservation solution. It consists of fully synthetic biomimetics of antifreeze proteins found in nature and bypasses the drawbacks of toxic molecules. This solution prevents damaging ice crystal formation during organ preservation at subzero temperature while supporting reduced metabolism and ischemic damage.

NON-TOXIC

ICE-FREE

MAKE TRANSPORT EASY WITH

TimeSeal® Smart Sensored Organ Transporter

TimeSeal® is a smart, portable, and easy-to-use transporterto safely and consistently transport organs. With its smart sensor technology, the organ can be tracked during transport with optimum temperature stability. TimeSeal® maintains functionality and viability for organs and for a wide range of therapeutic needs. TimeSeal® doesn‘t need any external power, perfusion, oxygen, or blood to keep the organs and tissues alive.

Effective. Controlled. Simple.

Simple transplant workflow

“No additional steps or equipment were needed. I used exactly the same methods as in clinical kidney transplantation.”

— Gerald Brandacher, MD, FAST; VP of Research and Scientific Director, Johns Hopkins Reconstructive Transplantation Program

Benefits of
XT-ViVo® & TimeSeal®

Extension of Time

XT-ViVo® will enable subzero preservation for 3-7 days compared to the 4-24 hours we have today.

TimeSeal® will provide a stable subzero environment.

Increased Transplant Availability

XT-ViVo® & TimeSeal® will eliminate geographic restriction, enabling organs, tissues, and cells to be shared around the world.

Better Transplant Quality

Subzero preservation is the most effective way to slow down metabolism and extend the life of an organ. XT-ViVo® eliminates ice phase transitions and reduces the risk of shock-induced ice damage during organ transport.

Smart & Easy Transportation

The TimeSeal® transport system contains an integrated intelligent sensor system that transmits real-time logistics data to the receiving team during transport. Simplicity and effectiveness in one platform. No supporting accessories such as blood, oxygen, or external power supply are required.

Medical Cost Reduction

Improved organ matching can shorten postoperative treatment time and reduce medication use.

Organ transplants can be scheduled in advance, eliminating middle-of-the-night and weekend procedures.

New Horizons

The ultimate XT-ViVo® and TimeSeal® system removes time from the equation for all regenerative medicines. We can not only transform how transplants are done today, but also offer essential infrastructure that makes centralized recovery, repair and rejuvenation of organs, tissues and cells possible, enabling cutting-edge Xeno-transplants and 3D printed organs to become clinical standard practice. Together, we can accelerate Organs-on-Demand by 10 years and save millions of lives.

"So important and exciting to explore new platforms that will be game-changers for extending organ preservation times by days and add to the advantages of organ perfusion when needed. A bright new future!"
Dr. David Mulligan
Past president at UNOS and Chair of Yale transplant center
NORTH AMERICA

625 Alfred Nobel Drive
Suite B
Hercules, CA 94547
USA

EUROPE

Kaiserjägerstraße 30
6020 Innsbruck
Austria